## SEC Form 4

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
--	--

C/O MPM CAPITAL 450 KENDALL STREET

MA

02142

(Street) CAMBRIDGE

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

# OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

									01 1040							
1. Name and Address of Reporting Person <sup>*</sup> MPM BioVentures 2014, L.P.				2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>iTeos Therapeutics, Inc.</u> [ ITOS ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner					
(Last) (First) (Middle) C/O MPM CAPITAL 450 KENDALL STREET				3. Date of Earliest Transaction (Month/Day/Year) 09/07/2021								Office below	r (give ti /)	tle	Oth belo	er (specify ow)
450 KEN	NDALL ST	REET		4. If Ame	endment, D	ate of Or	riginal	Filed (Month/D	Day/Yeai	·) (	6. Indi	ividual or	Joint/Gr	oup Filii	ng (Che	k Applicable
(Street) CAMBRIDGE MA 02142				<ul> <li>4. If Amendment, Date of Original Filed (Month/Day/Year)</li> <li>6. Individual or Joint/Group Filing (Check Applical Line)</li> <li>Form filed by One Reporting Person</li> <li>X</li> <li>Form filed by More than One Reporting Person</li> </ul>												
(City) (State) (Zip)																
		Table	I - Non-Deriva	ative Sec	curities	Acquir	red, I	Disposed o	of, or I	Benefic	cially	y Owne	ed			
1. Title of Security (Instr. 3) Date (Month/Day/Y			ar) 2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar		I (A) or . 3, 4 and	Beneficially Owned Following		s lly	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
						Code	v	Amount	(A) or (D)	Price	T	Reported Transaction(s) (Instr. 3 and 4)				
Common	Stock		09/07/202	1		S <sup>(1)</sup>		<b>30,474</b> <sup>(2)</sup>	D	\$29.18	3(3)	<sup>3)</sup> 3,635,313		13 I		See Footnote <sup>(4)</sup>
Common	Stock		09/07/202	1		J <sup>(5)</sup>		31,340 <sup>(6)</sup>	D	\$0.00	0	3,603,793		I See Foo		See Footnote <sup>(7)</sup>
Common Stock 09			09/08/202	1		S <sup>(1)</sup>		11,152 <sup>(8)</sup>	D	\$28.61	(9)	3,592,	,821	1	I	See Footnote <sup>(10)</sup>
Common Stock 09/08/202			1		S <sup>(1)</sup>		940(11)	D	\$29.1 <sup>(1</sup>	12)	3,591	,881	]	I	See Footnote <sup>(13)</sup>	
		Tal	ble II - Derivat (e.g., pu					sposed of s, converti				Owned	ł			
						· ·		xercisable and n Date Amount of ay/Year) 7. Title and Amount of Securities Underlying Derivative		7. Title and Amount of Securities Underlying Derivative Security (Instr.					-	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Inst 8)		hber 6. I Ex tive (Me sed	Date E piratio	xercisable and n Date	Amo Secu Unde Deriv Secu	unt of rities erlying rative rity (Instr.	De Sec (In:	Price of crivative curity Istr. 5)	9. Numb derivativ Securiti Benefici Owned Followin Reporte Transac (Instr. 4)	ve es ially ng ed stion(s)	10. Owners Form: Direct ( or Indir (I) (Inst	Beneficial D) Ownership ect (Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	Date	Execution Date, if any	Transactio Code (Inst	on of Deriva: Securi (A) or Dispos of (D) (Instr.: and 5)	hber tive tites ed 3, 4	Date E: piratio onth/D	xercisable and n Date ay/Year) Expiratior	Amo Secu Unde Deriv Secu 3 and	unt of rities erlying rative rity (Instr.	Dei Sei (Ins t	curity	derivativ Securiti Benefici Owned Followir Reporte Transac	ve es ially ng ed stion(s)	Owners Form: Direct ( or Indir	hip of Indirect Beneficial D) Ownership ect (Instr. 4)
Derivative Security (Instr. 3) 1. Name au	Conversion or Exercise Price of Derivative Security	Date	Execution Date, if any	Transactic Code (Inst 8)	on of Deriva: Securi (A) or Dispos of (D) (Instr.: and 5)	hber tive tites ed 3, 4	Date E: piratio onth/D	xercisable and n Date ay/Year) Expiratior	Amo Secu Unde Deriv Secu 3 and	unt of rities rlying vative rity (Instr. 1 4) Amount or Number of	Dei Sei (Ins t	curity	derivativ Securiti Benefici Owned Followir Reporte Transac	ve es ially ng ed stion(s)	Owners Form: Direct ( or Indir	hip of Indirect Beneficial D) Ownership ect (Instr. 4)
1. Name at MPM 1 (Last) C/O MP	Conversion or Exercise Price of Derivative Security Address of BioVentum	Date (Month/Day/Year)	Execution Date, if any	Transactic Code (Inst 8)	on of Deriva: Securi (A) or Dispos of (D) (Instr.: and 5)	hber tive tites ed 3, 4	Date E: piratio onth/D	xercisable and n Date ay/Year) Expiratior	Amo Secu Unde Deriv Secu 3 and	unt of rities rlying vative rity (Instr. 1 4) Amount or Number of	Dei Sei (Ins t	curity	derivativ Securiti Benefici Owned Followir Reporte Transac	ve es ially ng ed stion(s)	Owners Form: Direct ( or Indir	hip of Indirect Beneficial D) Ownership ect (Instr. 4)
1. Name at MPM 1 (Last) C/O MP	Conversion or Exercise Price of Derivative Security Address of Bio Ventur	Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year)	Transactic Code (Inst 8)	on of Deriva: Securi (A) or Dispos of (D) (Instr.: and 5)	hber tive tites ed 3, 4	Date E: piratio onth/D	xercisable and n Date ay/Year) Expiratior	Amo Secu Unde Deriv Secu 3 and	unt of rities rlying vative rity (Instr. 1 4) Amount or Number of	Dei Sei (Ins t	curity	derivativ Securiti Benefici Owned Followir Reporte Transac	ve es ially ng ed stion(s)	Owners Form: Direct ( or Indir	hip of Indirect Beneficial D) Ownership ect (Instr. 4)
1. Name at MPM 1 (Last) C/O MP	Conversion or Exercise Price of Derivative Security and Address of Bio Ventur M CAPITA NDALL STI	Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year)	Transactic Code (Inst 8)	on of Deriva: Securi (A) or Dispos of (D) (Instr.: and 5)	hber tive tites ed 3, 4	Date E: piratio onth/D	xercisable and n Date ay/Year) Expiratior	Amo Secu Unde Deriv Secu 3 and	unt of rities rlying vative rity (Instr. 1 4) Amount or Number of	Dei Sei (Ins t	curity	derivativ Securiti Benefici Owned Followir Reporte Transac	ve es ially ng ed stion(s)	Owners Form: Direct ( or Indir	hip of Indirect Beneficial D) Ownership ect (Instr. 4)
1. Name at MPM 1 (Last) C/O MP. 450 KEP (Street)	Conversion or Exercise Price of Derivative Security and Address of BioVentur M CAPITA NDALL ST UDGE	Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year)	Transactic Code (Inst 8)	on of Deriva: Securi (A) or Dispos of (D) (Instr.: and 5)	hber tive tites ed 3, 4	Date E: piratio onth/D	xercisable and n Date ay/Year) Expiratior	Amo Secu Unde Deriv Secu 3 and	unt of rities rlying vative rity (Instr. 1 4) Amount or Number of	Dei Sei (Ins t	curity	derivativ Securiti Benefici Owned Followir Reporte Transac	ve es ially ng ed stion(s)	Owners Form: Direct ( or Indir	hip of Indirect Beneficial D) Ownership ect (Instr. 4)
1. Name au MPM 1 (Instr. 3) (Last) C/O MP 450 KEN (Street) CAMBR (City) 1. Name au	Conversion or Exercise Price of Derivative Security and Address of Bio Ventur M CAPITA NDALL STI	Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year) (Middle) 02142	Transactic Code (Inst 8)	on of Deriva: Securi (A) or Dispos of (D) (Instr.: and 5)	hber tive tites and 3, 4	Date E: piratio onth/D	xercisable and n Date ay/Year) Expiratior	Amo Secu Unde Deriv Secu 3 and	unt of rities rlying vative rity (Instr. 1 4) Amount or Number of	Dei Sei (Ins t	curity	derivativ Securiti Benefici Owned Followir Reporte Transac	ve es ially ng ed stion(s)	Owners Form: Direct ( or Indir	hip of Indirect Beneficial D) Ownership ect (Instr. 4)

(City)	(State)	(Zip)					
1. Name and Address of <u>Foley Todd</u>	of Reporting Person <sup>*</sup>						
(Last) C/O MPM CAPITA 450 KENDALL ST		(Middle)					
(Street) CAMBRIDGE	MA	02142					
(City)	(State)	(Zip)					
1. Name and Address ( <u>MPM BioVentu</u>	of Reporting Person <sup>*</sup> 1 <u>res 2014 (B), L.</u>	<u>P.</u>					
(Last) C/O MPM CAPITA 450 KENDALL ST		(Middle)					
(Street) CAMBRIDGE	МА	02142					
(City)	(State)	(Zip)					
1. Name and Address ( <u>MPM Asset Ma</u> <u>LLC</u>	of Reporting Person <sup>*</sup> anagement Inves	tors BV2014					
(Last) C/O MPM CAPITA 450 KENDALL ST		(Middle)					
(Street) CAMBRIDGE	МА	02142					
(City)	(State)	(Zip)					
1. Name and Address of <u>MPM BioVentu</u>							
(Last) C/O MPM CAPITA 450 KENDALL ST		(Middle)					
(Street) CAMBRIDGE	MA	02142					
(City)	(State)	(Zip)					
1. Name and Address of Reporting Person* <u>MPM BioVentures 2014 GP LLC</u>							
(Last) C/O MPM CAPITA 450 KENDALL ST		(Middle)					
(Street) CAMBRIDGE	МА	02142					
(City)	(State)	(Zip)					
1. Name and Address ( <u>MPM BIOVEN</u>	of Reporting Person <sup>*</sup> ITURES 2018 (E	<u>3), L.P.</u>					
(Last) C/O MPM CAPITA 450 KENDALL ST (Street)		(Middle)					

CAMBRIDGE	МА	02142						
(City)	(State)	(Zip)						
1. Name and Address of Reporting Person* <u>MPM ASSET MANAGEMENT INVESTORS</u> <u>BV2018 LLC</u>								
(Last) C/O MPM CAPIT 450 KENDALL S		(Middle)						
(Street) CAMBRIDGE	MA	02142						
(City)	(State)	(Zip)						

### Explanation of Responses:

1. Transaction effected pursuant to a plan established pursuant to Rule 10b5-1.

2. The shares were sold as follows: 18,156 by MPM BioVentures 2014, L.P. ("BV 2014"), 625 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 11,467 by MPM BioVentures 2018, L.P. ("BV 2018") and 226 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014 (B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2014 (B). BV 2018 LLC is the manager of AM BV2018. Mesrs. Evnin and Foley are managing directors of BV 2018 and BV 2018 (LC and BV 2018 LLC) and BV 2018 LLC and BV 2018 LLC and BV 2018 (B). BV 2018 LLC is the manager of AM BV2018. Mesrs. Evnin and Foley are managing directors of BV 2018 and BV 2018 (LC) and BV 2018

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$28.89 to \$29.64 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The shares are held as follows: 2,050,714 by BV 2014, 128,561 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 70,585 by AM BV2014, 1,295,187 by BV 2018, 64,705 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)") and 25,561 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

5. Represents a pro rata in-kind distribution from BV 2014(B) and BV 2018(B) to its respective limited partners for no consideration.

6. The shares were distributed as follows: 20,848 by BV 2014(B) and 10,492 by AM BV 2018(B).

7. The shares are held as follows: 2,050,714 by BV 2014, 107,713 by BV 2014(B), 70,585 by AM BV2014, 1,295,187 by BV 2018, 54,213 by BV 2018(B) and 25,561 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

8. The shares were sold as follows: 6,644 by BV 2014, 229 by AM BV2014, 4,196 by BV 2018 and 83 by AM BV2018.

9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$28.02 to \$29.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

10. The shares are held as follows: 2,044,070 by BV 2014, 107,713 by BV 2014(B), 70,356 by AM BV2014, 1,290,991 by BV 2018, 54,213 by BV 2018(B) and 25,478 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

11. The shares were sold as follows: 560 by BV 2014, 19 by AM BV2014, 354 by BV 2018 and 7 by AM BV2018.

12. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$29.04 to \$29.21 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

13. The shares are held as follows: 2,043,510 by BV 2014, 107,713 by BV 2014(B), 70,337 by AM BV2014, 1,290,637 by BV 2018, 54,213 by BV 2018(B) and 25,471 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Page

#### Remarks:

See Form 4 for MPM BioVentures 2018, L.P for additional members of this joint filing.

/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 09/08/2021 2014 GP LLC, the general partner of MPM BioVentures 2014, L.P. <u>/s/ Luke Evnin</u> 09/08/2021 09/08/2021 /s/ Todd Foley <u>/s/ Ansbert Gadicke, managing</u> director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 09/08/2021 2014 GP LLC, the general partner of MPM BioVentures <u>2014 (B), L.P.</u> /s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the manager of 09/08/2021 MPM Asset Management Investors BV2014 LLC /s/ Ansbert Gadicke, managing director of MPM BioVentures 09/08/2021 2014 LLC /s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing 09/08/2021 member of MPM BioVentures 2014 GP LLC /s/ Ansbert Gadicke, managing 09/08/2021 director of MPM BioVentures 2018 LLC, the managing member of MPM BioVentures

2018 GP LLC, the general<br/>partner of MPM BioVentures2018 (B), L.P./s/ Ansbert Gadicke, managing<br/>director of MPM BioVentures2018 LLC, the manager of<br/>MPM Asset Management<br/>Investors BV2018 LLC

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.